Trial Profile
A Phase 1, Open‑Label, Three‑Period Randomized, Single Dose Study To Estimate The Relative Bioavailability Of Pf‑06291826 (Tafamidis) Free Acid Capsule Formulation Versus Commercial Capsule In Healthy Subjects Under Fasted Conditions
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Aug 2020
Price :
$35
*
At a glance
- Drugs Tafamidis meglumine (Primary)
- Indications Amyloid polyneuropathy; Cardiomyopathies
- Focus Pharmacokinetics
- Sponsors Pfizer
- 10 Aug 2016 Status changed from recruiting to completed.
- 13 Jul 2016 Planned End Date changed from 1 Jun 2016 to 1 Jul 2016.
- 13 Jul 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jul 2016.